Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 10Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Skin Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Mycosis Fungoides 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Carcinoma, Basal Cell 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Cisplatin 101Radiotherapy 53Brachytherapy 41Paclitaxel 37Carboplatin 36Surveys and Questionnaires 28Blood Specimen Collection 20pembrolizumab 19Radiation 17Magnetic Resonance Spectroscopy 17Drug Therapy 17Colposcopy 16Methods 14Bevacizumab 14Early Intervention, Educational 12toripalimab 11Topotecan 11Radiotherapy, Intensity-Modulated 11Papanicolaou Test 11Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Chemoradiotherapy 11Biopsy 11camrelizumab 10Mass Screening 10Gemcitabine 10Patient Navigation 9Papillomavirus Vaccines 9Nivolumab 9Fluorodeoxyglucose F18 9Educational Status 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Uterine Cervical Neoplasms × cemiplimab × Clear all
NCT06923761 2026-01-28

EMITT-1

Grey Wolf Therapeutics

Phase 1/2 Recruiting
300 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡